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Abstract
Background: The increased production of nanomaterials has caused a corresponding increase in concern about
human exposures in consumer and occupational settings. Studies in rodents have evaluated dose–response
relationships following respiratory tract (RT) delivery of nanoparticles (NPs) in order to identify potential hazards.
However, these studies often use bolus methods that deliver NPs at high dose rates that do not reflect real world
exposures and do not measure the actual deposited dose of NPs. We hypothesize that the delivered dose rate is a
key determinant of the inflammatory response in the RT when the deposited dose is constant.
Methods: F-344 rats were exposed to the same deposited doses of titanium dioxide (TiO2) NPs by single or
repeated high dose rate intratracheal instillation or low dose rate whole body aerosol inhalation. Controls were
exposed to saline or filtered air. Bronchoalveolar lavage fluid (BALF) neutrophils, biochemical parameters and
inflammatory mediator release were quantified 4, 8, and 24 hr and 7 days after exposure.
Results: Although the initial lung burdens of TiO2 were the same between the two methods, instillation resulted in
greater short term retention than inhalation. There was a statistically significant increase in BALF neutrophils at 4, 8
and 24 hr after the single high dose TiO2 instillation compared to saline controls and to TiO2 inhalation, whereas
TiO2 inhalation resulted in a modest, yet significant, increase in BALF neutrophils 24 hr after exposure. The acute
inflammatory response following instillation was driven primarily by monocyte chemoattractant protein-1 and
macrophage inflammatory protein-2, mainly within the lung. Increases in heme oxygenase-1 in the lung were also
higher following instillation than inhalation. TiO2 inhalation resulted in few time dependent changes in the
inflammatory mediator release. The single low dose and repeated exposure scenarios had similar BALF cellular
and mediator response trends, although the responses for single exposures were more robust.
Conclusions: High dose rate NP delivery elicits significantly greater inflammation compared to low dose rate delivery.
Although high dose rate methods can be used for quantitative ranking of NP hazards, these data caution against their
use for quantitative risk assessment.
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Nanoparticles (NPs) have diverse applications that have
proven to be beneficial to society. They are used in many
industrial processes (e.g., electronic, optical, mechanical)
for the manufacture of composite materials such as semi-
conductors and solar cells. They are also ingredients in sun-
screens and cosmetics, additives in odor-resistant clothing,
and filters for soil and water remediation. In the past dec-
ade, nanomaterials have emerged as pharmaceutical car-
riers and imaging agents in the biomedical field [1,2].
In fact, there are over 1,300 nanomaterial-containing
products on the market today [3]. The increased produc-
tion, consumer use and disposal of NP-containing prod-
ucts have led to a corresponding increase in the potential
for accidental or incidental human exposures via the in-
halation, dermal and ingestion routes as well as concerns
about environmental impacts. Indeed, nanotoxicological
research is focused on identifying and characterizing the
hazards associated with NPs with an overall goal of gener-
ating meaningful data for regulatory purposes.
Metal oxide NPs are of specific interest since some, such
as titanium dioxide (TiO2), are amongst the most widely
used NPs, produced in large volumes, and have been com-
mercially available in several shapes and sizes for decades.
The present study utilizes Evonik TiO2, which has been
used extensively in the toxicological literature and has
been previously well characterized [4,5]. For example,
in vivo studies have shown that subchronic and chronic
inhalation exposures to high concentrations of nanosized
TiO2 leads to lung inflammation, increased epithelial cell
proliferation, and even lung tumors in rats [6-9]. These
studies also provided evidence that nanosized TiO2 was
more potent than larger TiO2 particles when the depos-
ited mass doses were similar.
Many current experimental approaches for assessing
hazards from exposure to airborne nanoparticles use high
dose rate delivery (bolus exposure) combined with high
doses of particles. This does not reflect real-world expos-
ure conditions and can lead to overestimation of hazard
[10,11]. Intratracheal instillation is one such bolus delivery
technique, whereby NPs are suspended in liquid and rap-
idly delivered to the tracheobronchial and alveolar re-
gions of the respiratory tract (RT) of anesthetized animals,
and which results in uneven distribution of the material
[10,12]. Inhalation exposure, on the other hand, is the gold
standard for RT delivery of airborne NPs for toxicity as-
sessments, but is technically challenging and requires
large amounts of material. The greatest difference between
these bolus and aerosol delivery methods is the deposited
dose rate of the NPs to the RT.
We hypothesize that the deposited dose rate is a key de-
terminant of the acute inflammatory response in the RT.
In the present study, dose rate was varied while keeping
the deposited dose constant. Different exposure methods
were used to vary dose rate: intratracheal instillation was
the high dose rate delivery, which occurred within a frac-
tion of a second (~0.5 sec), and whole body inhalation was
the low dose rate delivery, which occurred over 4 hr. We
also varied the dose rate by employing repeated exposure
scenarios, which fractioned the same deposited dose over
4 days. Cellular and biochemical markers of acute lung in-
flammation and the levels of mediators that influence the
progression and resolution of the inflammatory response
were assessed. We demonstrate a higher inflammatory re-
sponse following intratracheal instillation compared to
whole body inhalation for single and repeated exposures
when deposited doses were held constant. Although we
did not evaluate the predictive power of intratracheal in-
stillation for NP risk assessment, our study reinforces the
need to carefully consider the use of bolus, high dose rate
delivery methods for risk characterization.
Results and discussion
The unique aspect of our study design was that the same
deposited doses were achieved via intratracheal instillation
and whole body inhalation, which allowed us to directly
compare the inflammatory responses on the basis of de-
posited dose rate. This is important not only because the
dose itself can determine the mechanism of response for
soluble compounds [13], but we also suggest the dose rate
and, therefore, underlying mechanisms may be different
between the two exposure methods for NPs.
Characterization of TiO2 size distributions in air and saline
Aerodynamic properties of TiO2 NPs
The size distributions of the material were assessed in
air and saline for inhalation and instillation exposures,
respectively (Table 1). The aerosol mass median aero-
dynamic diameter (MMAD) of 800 nm (geometric stand-
ard deviation, GSD 1.4) and count median diameter (CMD)
of 900 nm (1.8 GSD) were very similar and together
indicate that TiO2 N P sa g g l o m e r a t e di na i r .T h i si s
consistent with reports that aerosolized TiO2 tends to
agglomerate to ~0.7-1.5 μm in air whether the material
has a primary size in the micrometer range [7,14-16] or
Table 1 The size distribution characteristics of TiO2 in air
and saline
Medium Concentration Size distribution
Air 33± 4 mg/m
3 MMAD 800 nm, 1.4 GSD
CMD 900 nm, 1.8 GSD
Saline 80 μg/mL
DLS z-avg 1350 nm,
peak range 800–1700 nm
LDS mean 6363 nm,
peak range 900–11000 nm
MMAD, mass median aerodynamic diameter; CMD, count median diameter;
GSD, geometric standard deviation; DLS, dynamic light scattering (intensity
mode); LDS, laser diffraction spectroscopy (volume-based). DLS and LDS are
representative of 3 separate runs.
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the same at concentrations of 33±4 mg/m
3 or 13± 1 mg/m
3
and over the course of the exposures, indicating that the
animals were exposed to similarly sized agglomerates.
Hydrodynamic properties of TiO2 NPs
For instillation exposures, we assessed the hydrodynamic
diameter of TiO2 in saline within 15 min after it was indir-
ectly sonicated (cup horn) for 5 sec; all suspensions were
additionally vortexed for 30 sec immediately prior to meas-
urement. The suspension had an intensity-based average
hydrodynamic diameter (z-average) of 1350 nm, with a
single, broad peak with values ranging from 800–1700 nm
when assessed by dynamic light scattering (DLS) (Table 1).
Although DLS is a commonly used technique, it has dis-
advantages such as bias toward smaller particles and it
requires that suspensions be substantially diluted [17]. In-
deed, the TiO2 NP suspensions had to be diluted 1:10 in
order to obtain size distribution data, as the measurement
of the undiluted instillate was not possible. For these
reasons, we also assessed the hydrodynamic diameter using
laser diffraction spectroscopy (LDS) to determined the
volume-based size distribution of diluted suspensions (1:10)
and the mean was greater than 6 μmw i t hv a l u e sr a n g i n g
from 0.9–11 μm (Table 1), although 10% of the sample was
a separate, broad peak at ~9 μm( data not shown). Import-
antly, by either DLS or LDS, similar hydrodynamic diame-
ters were observed for up to 1 hr post sonication (data not
shown), indicating that the agglomeration state of the ma-
terial was consistent for each animal that was instilled.
We also assessed the hydrodynamic diameter for the low
dose studies and the repeated exposure studies and found
them to be consistent with size distributions as reported
in Table 1 (data not shown). The DLS and LDS measure-
ments cannot be directly compared because LDS measures
across a wider range of particle sizes (10 nm to thousands
of nm) and does not neglect particle settling or the pres-
ence of large agglomerates [18]. Likewise, it is not possible
to directly compare hydrodynamic and aerodynamic par-
ticle size distributions because of inherent differences in
analytical tools and in the concentrations of airborne and
saline suspended NPs.
These data regarding airborne particles or liquid sus-
pension of particles do not address the size distribution
of the particles in the lung upon deposition and interac-
tions with lung lining fluid. We presume that the size dis-
tribution of the material within the lung may differ based
on delivery method from previous work [10,12,19]. These
studies showed that intratracheal instillation results in
more proximal and uneven distribution in the lung,
whereas whole body inhalation results in more even distri-
bution within the lung, including deposition to more distal
regions and some carinal hotspots [20]. In fact, the inflam-
matory cell influx following deposition of similar lung
burdens of fine and ultrafine TiO2 were higher following
intratracheal instillation compared to intratracheal inhal-
ation exposure in a study by Osier and Oberdörster [21],
although inflammatory mediator release was not assessed.
These differences were attributed to both differences in
dose rate and unevenness of distribution. Furthermore,
Henderson et al. [22] reported greater inflammatory ef-
fects of similar lung burdens of α-quartz 1 week following
repeated inhalation compared to single instillation, where
the inhalation animals were subjected to whole lung lav-
age and the instilled animals only had right lobes lavaged.
Therefore, potential response differences due to uneven
distribution of the material were not taken into account.
Since unevenness of distribution may have played a role
in response outcomes in our study, we employed whole-
lung lavage. However, it is still unclear if unevenness of
deposition alone is linked to mechanistic differences in re-
sponse; further investigation would be beyond the scope
of this manuscript.
Dosimetry
Initial lung burden of TiO2 NPs
The first aim of these studies was to achieve the same
initial lung burden (ILB) into the lower RT for both
intratracheal instillation and whole body inhalation ex-
posures. Several studies have compared inhalation to
intratracheal instillation [22-26] or with other bolus deliv-
ery methods, such as pharyngeal aspiration [27,28]. How-
ever, these studies reported estimated deposited doses
without confirming them. Because model estimates can
deviate significantly from actual values, we measured and
used for comparison the actual deposited doses in unla-
vaged lungs immediately following exposure (Table 2).
Whole body inhalation ILBs were not found to be statisti-
cally significantly different from intratracheal instillation
ILBs; high dose single and repeated exposures also had
similar deposited doses of TiO2. We assume that the TiO2
we quantified in the lung was in the particulate form
based on results from a 7 day dissolution experiment,
where levels of soluble Ti were below the instrument level
of detection (data not shown). The poor solubility of TiO2
has been well recognized for decades, although recent
findings by Al-Jubory and Handy [29] suggested that
nanosized TiO2 NPs release up to 6.9 μg Ti/hr in simu-
lated piscine intestinal fluid.
Table 2 Initial lung burdens of TiO2
Exposure type Whole body
inhalation
Intratracheal
instillation
Single low dose (μg) 44.56 ± 2.85 39.24 ± 1.04
Single high dose (μg) 170.25 ± 9.15 163.58 ± 3.84
Repeated high dose (μg) 197.89 ± 8.89 179.61 ± 17.14
Values are group means (n = 3–5) of NP mass doses (μg) ± standard deviation
(SD) immediately following instillation and 4 hr inhalation exposures.
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cit about expressing dose to the lung. For example,
Mizuguchi et al. [30] described the “deposited dose” of
NiO in their instillation/inhalation comparison study
and Yamamoto et al. [31] quantified the dose of potas-
sium hexatitanate that was instilled or inhaled; however,
in both of these studies, measurements were performed
3 days after exposure. Such measurements characterize
short term alveolar retention of the material, not ILB.
Short term retention of TiO2 NPs
Short term retention was evaluated over a 7 day period
following the single, high dose exposures in lungs that
were not lavaged (Figure 1A). Although the instillation
and inhalation ILBs were similar, the short term retention
patterns were different, with statistically significant de-
creases over time following inhalation, but little change
for instilled animals. Within the first 24 hr following inhal-
ation exposure, clearance is likely due to the mucociliary
transport of the deposited TiO2 NPs from the tracheo-
bronchial region and the posterior portions of the nasal
passages [32]. At 7 days, clearance is likely from the alveo-
lar region. Some studies have suggested that deag-
glomerated, nanosized TiO2 can reach the interstitium and,
potentially, the vasculature during the clearance process
[7,33-38]. We did not detect TiO2 in the blood at 24 hr or
7 days post exposure (data not shown) and translocation to
secondary organs was not evaluated in this study.
Even though the clearance of particles from the alveo-
lar region would begin immediately after exposure, it
would take several months for the particles to fully
clear from the RT [32] (T1/2 ~70 days). We assume that
the short term retention profiles for the two exposure
methods are different because the dissimilar deposition
patterns, higher local dose per unit time, and the ensuing
inflammation following instillation of TiO2 (Figure 2C)
may have perturbed the clearance. Furthermore, previous
findings demonstrated that over several months, the long
term clearance patterns (> 7 days) are similar for the two
exposure methods, both at low and high lung TiO2 bur-
dens [39].
Compartmentalization of TiO2 NPs in BALF supernatant,
BALF cell pellet and lavaged lung tissue
We assessed the compartmentalization of deposited
TiO2 in the RT, namely in BALF supernatant, pellet and
lavaged lung 24 hr post exposure (Figure 1B). The
compartmentalization patterns of the instilled and in-
haled animals are identical, with the majority of the mater-
ial being associated with lavaged cells or lung parenchyma
(inside or firmly attached to cells). Ferin et al. [40] also re-
ported similar findings, where ~69% of instilled ultrafine
TiO2 was recovered in the BALF pellet and ~30% in
the remaining lung tissue. Geiser et al. [37] docu-
mented similar findings at 1 hr and 24 hr post inhal-
ation of ultrafine TiO2 in rats: on average, ~79% of the
particles were on the luminal side of the airway and al-
veolar surfaces, ~5% were inside epithelial or endo-
thelial cells, ~5% in connective tissues and ~11% in
capillary lumens. Kapp et al. [36] also reported TiO2 in-
ternalization in type I pneumocytes.
Within the BALF pellet, we expect that the material
is associated with macrophages, specifically, given that
with 5 lavages the majority of the extracted cells (~60%)
are macrophages (Figure 2B) [34]. This would therefore
leave ~40% of the macrophages in the lung, meaning
that they are still a predominant cell type in the al-
veolar sacs, likely interacting with the TiO2.O t h e r
Figure 1 Dosimetry and short term retention of TiO2 for single
high dose TiO2 exposure. The mass of TiO2 deposited in the lung
following whole body inhalation (blue squares) and intratracheal
instillation (green circles) was determined immediately, 24 hr and 7
days post exposure (A) and the compartmentalization of TiO2 in BALF
supernatant, BALF cell pellet and the remaining lung tissue after lavage
(lavaged lung) were determined 24 hr post exposure (B).V a l u e sa r e
group means (n = 3–5) ± standard error (SE). The inhalation and
instillation ILBs were not found to be significantly different; *,
significantly different compared to the respective ILB (p < 0.05).
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tween nanomaterials and cells are necessary in order
to elicit or enhance an inflammatory response or me-
diator release [41-43], and numerous in vitro studies
have demonstrated that uptake and mechanisms may
be cell type dependent. Our data show that the TiO2
NPs were primarily cell associated (inside or firmly
attached to cells) and elicited a significant, acute in-
flammatory response in the RT in vivo.
Lung inflammatory responses following single exposure
to high and low doses of TiO2 NPs
Impact of dispersant on TiO2 NP-induced neutrophil influx
Many in vitro and in vivo studies use coatings, such as
surfactants, in order to mimic the lung lining fluid in an
in vivo scenario [44] and/or to obtain monodisperse, sta-
bilized suspensions [45]. Here, we did not use coatings
because: 1) real world RT exposures do not involve
monodispersed NPs [46]; 2) upon deposition into the
lung, particles will interact with lung lining fluid and
become coated with proteins and other biomolecules;
3) regardless of the suspension coating or dispersion at
the time of exposure, particles may agglomerate within
the lung upon deposition [47]; 4) we wanted to keep the
material as pristine as possible for better comparison to
the uncoated, pristine material used for inhalation; and,
5) in a pilot study, we determined that pretreatments
with coating or sonication can modify the inflamma-
t o r yr e s p o n s e( A d d i t i o n a lf i l e1 :F i g u r eS 1 ) .W ef o u n d
that pretreatment with dispersion medium (DM; 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine + albumin in
saline [48]) resulted in significantly lower neutrophil in-
flux than with saline alone (Additional file 1: Figure S1A).
These findings are consistent with a study by Morimoto
et al. [49] where fullerenes prepared with a 0.1 mg/mL
coating of Tween-80 were not able to induce inflamma-
tory effects when delivered by either whole body inhal-
ation or intratracheal instillation. In addition, we observed
that increased sonication time led to a significant decrease
in neutrophil influx (Additional file 1: Figure S1B). In
order to detect quantifiable differences between instilled
and inhaled animals for our study, we kept the material as
pristine as possible by suspending the material in saline
and using only a 5 sec sonication time. Nonetheless, our
findings regarding the impact of dispersant and sonication
time on acute inflammation provide additional caveats
when performing and interpreting results from studies
that employ bolus delivery of NPs.
Figure 2 Time course of changes in BALF cellular and biochemical parameters following single high dose exposure to TiO2 NPs. The
numbers of cells (A), macrophages (B), and neutrophils (C), and LDH (D) and β-glucuronidase activities (E) were assessed 4, 8, 24 hr and 7 days
post inhalation (blue squares) or instillation (green circles) exposure. Values are group means± SE (n= 5) and are represented as a percentage of
respective controls. *, significantly different from corresponding controls; Φ, significantly different between exposure methods (p<0.05).
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following single high dose TiO2 NP exposure at high and
low deposited dose rates
We performed single high dose exposures by whole body
inhalation or intratracheal instillation and collected
BALF to assess inflammatory response induction and
resolution over a 7 day period (Figure 2 and Table 3).
The response endpoints are plotted in Figure 2 as a per-
centage of corresponding control in order to clearly de-
pict the differences in response over time between the
two exposure methods. All raw data appear in Table 3.
After an initial decrease, BALF cell numbers increased
significantly 24 hr after intratracheal instillation with
TiO2; this effect was also significantly higher than the
corresponding inhalation exposure group (Figure 2A and
Table 3). The cell number changes were resolved within
7 days post exposure, despite the fact that TiO2 was
still present in the lung. There were no time dependent
changes in cell number following TiO2 inhalation.
Overall, there were no statistically significant eleva-
tions in macrophages that would explain the observed
changes in total cell numbers (Figure 2B and Table 3).
There was a transient decrease following instillation ex-
posure that could have been due to adhesive changes.
Not surprisingly, there were also no changes in the num-
ber (or percentage) of lymphocytes in BALF (Table 3).
The change in total cell number, thus, was primarily due
to neutrophil influx (Figure 2C and Table 3). We
Table 3 BALF cellular and biochemical parameters following single exposures to TiO2 NPs at different dose rates
A) Whole body inhalation
Air Controls TiO2
Post exposure time 4 hr 8 hr 24 hr low dose 24 hr high dose 7 days
Cell viability (%) 95.6 ± 1.2 95.1 ± 0.7 94.9 ± 0.9 94.7 ± 1.0 92.5 ± 2.3 95.5 ± 1.4
Total cells (Number ×10
7) 1.39 ± 0.21 1.53 ± 0.07 1.41 ± 0.10 1.62 ± 0.14* 1.32 ± 0.07 1.41 ± 0.16
Alveolar macrophages (%) 99.2 ± 0.3 98.7 ± 1.1 98.6 ± 0.7 97.6 ± 0.9 92.7 ± 1.4 99.0 ± 0.5
(Number × 10
7) (1.36 ± 0.2) (1.52 ± 0.07) (1.39 ± 0.11) (1.58 ± 0.12) (1.22 ± 0.07) (1.40 ± 0.16)
Neutrophils (%) 0.5 ± 0.1 0.7 ± 0.9 0.8 ± 0.6 1.6 ± 0.6 6.2 ± 1.5 0.6 ± 0.4
(Number × 10
5) (1.26 ± 0.69) (1.01 ± 1.41) (1.14 ± 0.70) (2.59 ± 1.08) (8.18 ± 1.86)* (0.89 ± 0.56)
Lymphocytes (%)
a 0.3 ± 0.3 0.6 ± 0.3 0.4 ± 0.3 0.8 ± 0.4 1.1 ± 0.2 0.6 ± 0.4
(Number ×10
4)
b (3.92 ± 3.31) (10.12 ± 14.05) (5.41 ± 4.91) (13.92 ± 7.67) (14.89 ± 2.34) (8.45 ± 4.99)
LDH release (nmol/min/mL) 39.82 ± 3.98 49.31 ± 4.91* 55.01 ± 3.18* 59.91 ± 19.37 38.93 ± 4.99 42.31 ± 2.37
β-Glucuronidase activity
(nmol/min/mL)
c
0.18 ± 0.03 0.08 ± 0.03* 0.11 ± 0.03* 0.37 ± 0.11* 0.20 ± 0.02 .20 ± 0.03
BALF Protein (mg/mL)
c 0.13 ± 0.01 0.14 ± 0.02 0.13 ± 0.02 0.08 ± 0.02* 0.15 ± 0.01 0.12 ± 0.04
B) Intratracheal instillation
Saline Controls TiO2
Post exposure time 4 hr 8 hr 24 hr low dose 24 hr high dose 7 days
Cell viability (%) 95.6 ± 1.1 96.0 ± 0.3 94.7 ± 1.3 94.1 ± 0.8 94.5 ± 1.7 93.7 ± 0.7
Total cells (Number ×10
7) 1.52 ± 0.18 1.39 ± 0.14 1.40 ± 0.32* 1.66 ± 0.08 2.09 ± 0.11*Φ 1.50 ± 0.06
Alveolar macrophages (%) 98.4 ± 0.3 95.0 ± 2.6 89.4 ± 6.9*Φ 95.5 ± 1.4 67.7 ± 3.1*Φ 96.6 ± 1.3
(Number 10
7) (1.54 ± 0.12) (1.32 ± 0.11) (1.23 ± 0.17)* (1.59 ± 0.09) (1.41 ± 0.08) (1.45 ± 0.04)
Neutrophils (%) 1.0 ± 0.2 3.8 ± 2.8*Φ 9.8 ± 7.1*Φ 3.7 ±1.4* 31.1 ± 2.6*Φ 1.9 ± 1.7
(Number × 10
5) (1.47 ± 0.43) (5.52 ± 4.35)*Φ (15.46 ± 15.42)*Φ (6.10 ± 2.31)*Φ (65.02 ± 6.56)*Φ (2.84 ± 2.66)
Lymphocytes (%)
a 0.7 ± 0.3 0.7 ± 0.2 0.8 ± 0.3 0.8 ± 0.1 1.2 ± 0.8 0.9 ± 0.2
(Number ×10
4)
b (9.55 ± 2.68) (9.95 ± 3.03) (10.33 ± 3.76) (13.74 ± 1.18) (25.00 ± 18.38) (13.19 ± 3.34)
LDH release (nmol/min/mL) 46.32 ± 7.36 47.99 ± 3.78 55.19 ± 5.76 68.01 ± 9.12* 76.59 ± 4.15*Φ 58.60 ± 4.22*Φ
β-Glucuronidase activity
(nmol/min/mL)
c
0.22 ± 0.03 0.10 ± 0.03* 0.15 ± 0.02* 0.30 ± 0.06 0.52 ± 0.07*Φ 0.30 ± 0.05*Φ
BALF protein (mg/mL)
c 0.12 ± 0.02 0.16 ± 0.02 0.18 ± 0.01*Φ 0.07 ± 0.00* 0.14 ± 0.02 0.11 ± 0.01
Values are group means (n = 5)± SD for inhalation (4 hr duration) and instillation exposures at 4, 8, 24 hr and 7 days post beginning of exposure. *, significantly
different from corresponding controls; Φ, significantly different from whole body inhalation at the same post-exposure time point;
a, main effects of both time
and exposure method;
b, main effect of exposure method (p< 0.05);
c, one outlier was identified through analysis of the residuals and removed.
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8 and 24 hr post TiO2 instillation and a small transient
increase in neutrophil number 24 hr after inhalation
exposure. The magnitude of the neutrophil response fol-
lowing instillation is more than 4 times higher compared to
inhalation exposure when the response is at its peak.
By 7 days post exposure, the inflammatory cell changes
had completely resolved regardless of exposure method.
Our findings of peak inflammation occurring 24 hr after
exposure are consistent with historical data from our
laboratory and other published findings [34,50-53].
We also evaluated LDH release and β-glucuronidase ac-
tivities (Figure 2D & E) in order to determine if deposited
dose rate influences the cell membrane integrity or lyso-
somal membrane integrity, respectively. We observed that
these response patterns followed similar trends as the cellu-
lar data, as expected, except that the instillation response
did not fully resolve within 7 days. The apparently overlap-
ping symbols in Figure 2E are a result of depicting the data
as percent of control, meaning the saline and air controls
have slightly different baseline values. Despite the small in-
creases in LDH and β-glucuronidase activities, there was no
change in lavage cell viability (Table 3) following exposure
to TiO2 by either exposure method. Furthermore, BALF
protein levels, indicative of epithelial barrier permeability
changes (Table 3), were only transiently increased 8 hr after
instillation exposure. These findings confirm previous re-
ports that TiO2 is not directly cytotoxic, especially with a
lung deposited dose in the microgram range [15,54-57].
Inflammatory cell influx and BALF biochemical parameters
following single low dose TiO2 NP exposure at high and low
deposited dose rates
By incorporating a lower deposited dose into the study de-
sign, we were able to better characterize the impact of dose
rate on responses to TiO2 NPs. We chose to evaluate re-
s p o n s e so n l y2 4h ra f t e re x p o s u r e ,a st h i si sw h e nt h em o s t
robust inflammatory responsesw e r ef o u n da tt h eh i g h e rd e -
posited dose. We observed dose dependent increases in total
cell number and neutrophil influx and only transient in-
creases in macrophages following instillation (Figure 3 and
Table 3). After inhalation, there was a significant increase in
cell number at the low dose, due to small increases in mac-
rophages and neutrophils. Although inhalation exposure did
result in dose dependent increases in neutrophils, these
were significantly lower in magnitude as compared to instil-
lation at the lower deposited dose (Figure 3C and Table 3).
LDH and β-glucuronidase increased in a dose dependent
manner following instillation, with only transient increases
at the lower dose following inhalation (Figures 3D and E,
Table 3). Overall, however, these data show more robust re-
sponses by instillation than inhalation at both doses, con-
f i r m i n gt h a td o s er a t ep l a y sar o l ei nt h ei n f l a m m a t o r y
response at lower deposited doses as well as higher doses.
Inflammatory mediator release and oxidative stress levels
following single TiO2 NP exposures at high and low
deposited dose rates
We measured several inflammatory mediators by ELISA
in order to identify the drivers of the neutrophil responses
following instillation and inhalation exposures to TiO2
and to determine if the mechanisms of response are differ-
ent based on dose rate. Several studies have demon-
strated links between NP exposure, oxidative stress and
pro-inflammatory mediator release [51,58,59]. We selected
mediators that are well-documented in the nanotoxicology
literature as playing a role in RT inflammation, namely:
monocyte chemoattractant protein-1 (MCP-1), macro-
phage inflammatory protein-2 (MIP-2), tumor necrosis fac-
tor alpha (TNF-α) and interleukin-10 (IL-10) (Figure 4 and
Table 4). For example, MCP-1 has been shown to induce
neutrophil chemotaxis to the lungs in response to inflam-
matory stimuli [60]. Similarly, MIP-2, the rat homologue
of human IL-8, has been implicated in the aforementioned
studies as a key mediator in the inflammatory response
and is released by several cell types, including type II alveo-
lar epithelial cells and alveolar macrophages. Another
study suggested that TNF-α was involved with the stimula-
tion of MIP-2 mRNA transcription for enhanced neutro-
phil chemotaxis [61]. Regarding TiO2 NP exposure and the
induction of the inflammatory response, specifically, 1–10
nm (0–800 μg/mL) nanosized TiO2 was found to induce
the production of IL-8 by freshly isolated human PMNs
[62]. In addition, IL-10 levels were increased along with
the total number of neutrophils in the lungs of rats for 1–2
days after instillation exposure to 1, 5 and 7.5 mg/kg
TiO2, indicating increases in inflammation, which resolved
within 16 days of exposure [63].
In the present studies, intratracheal instillation resulted
in significant increases in MCP-1 in both homogenized
lung tissue and BALF (Figure 4A and E, Table 4). There
was, however, no significant change in MCP-1 in the ani-
mals exposed to TiO2 NPs by inhalation, suggesting that it
did not play a significant role in the small but statistically
significant neutrophil influx that was observed (Figures 2
and 3; Table 3). MCP-1 was the only inflammatory medi-
ator that we found to have higher concentrations in the
BALF than the lung homogenates. This is likely due to
MCP-1 being released by the neutrophils themselves
following recruitment into the lung, thus propagating the
inflammatory response [64]. Also, MCP-1 was the only
significantly increased inflammatory mediator following
low dose single exposure to TiO2 NPs (Table 4). MIP-2
showed statistically significant increases from controls in
lung homogenates following high dose instillation, and
this response was also significantly higher than the MIP-2
released following inhalation in the early phase of the in-
flammatory response (Figure 4B and Table 4). In BALF,
the MIP-2 response was more variable (Figure 4F and
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ferent between the exposure methods, there were no sta-
tistically significant changes. TNF-α had similar trends to
the MIP-2 release in the homogenates, but the overall re-
sponse was lower (Figure 4C and Table 4). TNF-α was not
detectable in BALF. We also evaluated the release of an
anti-inflammatory cytokine, IL-10, in order to characterize
the resolution of the response (Figure 4D and Table 4),
and observed only a main effect of exposure method.
Based on our findings regarding patterns of release of
MCP-1, MIP-2, TNF-α and IL-10, we conclude that these
mediators played a role in driving the inflammatory re-
sponse to TiO2 NPs that are delivered via instillation, but
not inhalation. Certainly, there are other mediators that
can be investigated to further characterize the differences
in response by both exposure methods. Thus, we have built
upon the findings of Slikker et al. [13] – that the dose deter-
mines the mechanism – by suggesting that the mechanisms
of the inflammatory response to TiO2 are inherently
different when it is deposited at different dose rates.
We also evaluated changes in the early oxidative stress
marker, heme oxygenase-1 (HO-1; Figure 5 and Table 4),
which has been shown to increase in target cells that are
exposed to NPs in vitro [65]. Previous studies have shown
that type II cells and alveolar macrophages produce HO-1
in response to TNF-α release [66,67]. Here, we saw signifi-
cant increases in lung homogenate HO-1 following instil-
lation of TiO2 as compared to corresponding controls and
with respect to animals that were exposed by inhalation at
4, 8 and 24 hr post exposure (Figure 5A and Table 4).
Interestingly, the HO-1 levels in BALF cell pellets only
modestly increased over time and the trend was similar
for either method, indicating that its production by lung
inflammatory cells was not affected by the deposited dose
rate like it was in the lung tissue (Figure 5B and Table 4).
Lung inflammatory responses following repeated
exposures to a high dose of TiO2 NPs
In order to further characterize the effects of dose rate,
we fractioned the deposited dose over 4 consecutive days
of exposures either by intratracheal instillation or whole
body inhalation. This exposure scenario effectively chan-
ged the rate at which the total mass of TiO2 was de-
posited into the lung to much lower rates than with
single exposures (0.21 μg/min, repeated inhalation;
0.71 μg/min, single inhalation; 5400 μg/min, repeated
instillation; 200,000 μg/min single instillation). The total
deposited amounts are shown in Table 2 and, again, were
Figure 3 Dose response relationships for BALF cellular and biochemical parameters 24 hr post exposure to TiO2 NPs. The numbers of
cells (A), macrophages (B), and neutrophils (C), and LDH (D) and β-glucuronidase activities (E) 24 hr post inhalation (blue squares) or instillation
(green circles) exposure to increasing deposited doses of TiO2 NPs. Values are group means±SE (n=5) and are represented as a percentage of
respective controls. *, significantly different from corresponding controls; Φ, significantly different between exposure methods (p<0.05).
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ure methods. The total number of cells, macrophages
and neutrophils were all significantly increased from
control values following instillation and were also sig-
nificantly greater than responses observed following
TiO2 inhalation (Figure 6 and Table 5). LDH release
was significantly increased by repeated inhalation and
instillation exposures (Figure 6D); no significant
changes were detected for β-glucuronidase activity
(Figure 6E). Similar to the single exposure scenario,
there were also no statistically significantly different
changes observed in cell viability following repeated
exposure (Table 5). Statistically significant differences
from control or between exposure methods were not
observed for BALF protein, only a statistically signifi-
cant main effect of TiO2 exposure (Table 5). Overall,
the effects of deposited dose rate for the repeated ex-
posure model were similar to what was observed following
single exposures, except that repeated exposure apparently
dampened the inflammatory response. This may be due to
animals undergoing adaptation as has been observed with
other inflammatory stimuli [68,69]. Also, the number and
percentages of lymphocytes were significantly increased
following repeated instillation exposure, which is also an
indicator of adaptation [70]. Indeed, the repeated exposure
model confirms the importance of dose rate when design-
ing experiments to characterize risks associated with NPs
in humans.
Figure 4 Inflammatory mediator release in lung homogenates and BALF supernatants following single high dose exposure to TiO2
NPs. Changes in MCP-1 (A, homogenates; E, BALF supernatants), MIP-2 (B, homogenates; F, BALF supernatants), TNF-α (C, homogenates) and IL-10,
(D, homogenates) following inhalation (blue squares) or instillation (green circles) are graphed as percentage of controls. Values are group means±
SE (n=5). ND, levels were below the limit of detection by ELISA (TNF-α and IL-10 ~15 pg/mL). *, significantly different from corresponding controls;
Φ, significantly different between exposure methods (p<0.05).
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The role of dose rate based on neutrophil influx follow-
ing both repeated and single high dose exposures is rep-
resented in Figure 7, with response plotted as a function
of the deposited dose rate. Clearly, as deposited dose
rate increases, there is a corresponding increase in the
neutrophil response. TiO2 instillation not only resulted
in significantly more robust neutrophil influx, but also
increases in LDH and β-glucuronidase activities, and
MCP-1, MIP-2 and TNF-α inflammatory mediator re-
lease in lung homogenates when compared to controls
and to TiO2 inhalation. MCP-1 in BALF supernatants
and HO-1 levels in lung homogenates were also signifi-
cantly increased from controls and compared to inhal-
ation. Although there are several other inflammatory
mediators and oxidative stress endpoints that could be
investigated, the present results demonstrate that the
high deposited dose rate exposures elicited higher in-
flammation due to signaling from the lung parenchyma
as well as resident and infiltrating inflammatory cells.
Whole body inhalation exposure to TiO2 NPs resulted
in a low level, but statistically significant neutrophil re-
sponse that was evident at 24 hr post exposure when
compared to air exposed animals, with few statistically
significant differences in the other response endpoints.
These findings suggest that the inflammatory response
following low dose rate inhalation exposure was initiated
by resident inflammatory cells in the lung. Regardless of
the exposure method, the inflammatory response had
largely subsided by 7 days post exposure, despite the fact
that TiO2 NPs still remained in the lungs.
Our findings regarding the role of dose rate in TiO2
NP induced inflammatory response outcomes may only
be relevant for other poorly soluble NPs. Indeed, when the
same deposited dose of oil combustion particles, which
are more reactive than TiO2 and a mixture of metal
oxides, were delivered by intratracheal instillation or
nose-only inhalation, the neutrophil, BALF protein, lung
histopathology and airway responsiveness endpoints were
similar between the two methods [71]. Therefore, further
investigations to elucidate the mechanisms of response
following different dose rate deliveries are needed for
more reactive metal and metal oxide NPs. Post exposure
(60–90 days) evaluation of the lung tissue histopathology
would also provide further characterization of the reso-
lution of the acute inflammatory response.
Table 4 Inflammatory mediator and oxidative stress release in BALF and lung homogenates following TiO2 NP
exposure at different dose rates
A) Whole body inhalation
Air Controls TiO2
Post exposure time 4 hr 8 hr 24 hr low dose 24 hr high dose 7 days
BALF MCP-1 (pg/mg protein) 5878 ± 1292 6879 ± 3514 7285 ± 4762 17620 ± 3629* 6936 ± 1590 9112 ± 1977
BALF MIP-2 (pg/mg protein) 1592 ± 456 1022 ± 787 893 ± 491 957 ± 343 1696 ± 194 1526 ± 424
Homogenate MCP-1 (pg/mg protein) 578 ± 52 564 ± 64 551 ± 18 527 ± 68 582 ± 72 621 ± 39
Homogenate MIP-2 (pg/mg protein) 18.85 ± 3.84 13.76 ± 1.36 14.21 ± 1.88 18.59 ± 3.67 15.23 ± 4.02 19.29 ± 2.91
Homogenate TNF-α (pg/mg protein) 4.66 ± 0.71 4.14 ± 0.95 4.21 ± 0.42 4.79 ± 0.56 4.23 ± 0.75 4.22 ± 0.32
Homogenate IL-10 (pg/mg protein)
a 10.85 ± 0.74 9.53 ± 0.99 10.16 ± 0.60 10.12 ± 1.14 10.16 ± 1.22 9.71 ± 1.20
Homogenate HO-1 (ng/mg protein) 1.62 ± 0.15 1.45 ± 0.10 1.69 ± 0.41 1.56 ± 0.19 1.74 ± 0.18 1.60 ± 0.25
BAL pellet HO-1 (ng/mg protein)
b 101 ± 14 91 ± 53 118 ± 28 104 ± 9 134 ± 13 121 ± 11
B) Intratracheal instillation
Saline Controls TiO2
Post exposure time 4 hr 8 hr 24 hr low dose 24 hr high dose 7 days
BALF MCP-1 (pg/mg protein) 9026 ± 2037 10770 ± 5619 12590 ± 3402 19340 ± 1913.70* 66450 ± 8421*Φ 18430.00 ± 3593*
BALF MIP-2 (pg/mg protein) 2008 ± 2486 2114 ± 1309 1932 ± 501 1413 ± 412 779 ± 508 1240 ± 428
Homogenate MCP-1 (pg/mg protein) 1084 ± 231Φ 1774 ± 525*Φ 2084 ± 473*Φ 429 ± 40* 1647 ± 287*Φ 1087 ± 249Φ
Homogenate MIP-2 (pg/mg protein) 8.64 ± 2.71Φ 21.23 ± 2.68*Φ 30.53 ± 5.86*Φ 6.78 ± 0.64*Φ 11.87 ± 4.29 13.12 ± 1.97
Homogenate TNF-α (pg/mg protein) 3.86 ± 0.89 5.19 ± 0.54 5.51 ± 0.68* 3.76 ± 0.59 4.44 ± 0.53 4.21 ± 0.37
Homogenate IL-10 (pg/mg protein)
a 8.83 ± 2.12 10.26 ± 2.61 9.79 ± 1.77 7.27 ± 1.41 8.82 ± 2.10 7.22 ± 1.22
Homogenate HO-1 (ng/mg protein) 1.80 ± 0.58 2.79 ± 0.42*Φ 2.56 ± 0.17*Φ 1.27 ± 0.08* 3.38 ± 0.49*Φ 1.51 ± 0.34
BAL pellet HO-1 (ng/mg protein)
b 101 ± 16 96 ± 6 124 ± 15 114 ± 17 135 ± 31 118 ± 6
Values are group means (n = 5)± SD for inhalation (4 hr duration) and instillation exposures at 4, 8, 24 hr and 7 days post beginning of exposure. *, significantly
different from corresponding controls; Φ, significantly different from whole body inhalation at the same post-exposure time point;
a, significant main effect of
exposure method;
b, significant main effect of time (p< 0.05).
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The deposited dose rate determines the mechanism and
magnitude of the acute inflammatory response in the RT
when the ILBs are the same. Our data suggest that
results from intratracheal instillation exposure studies
overestimate acute TiO2 NP toxicity and that careful con-
sideration should be given to dose rate in the context of
risk characterization. However, intratracheal instillation
could still be appropriate for hazard ranking (i.e., compar-
ing one nanomaterial to another). We presume that our
conclusion that increased dose rate results in increased
response outcomes is not specific to TiO2 NPs and that
this phenomenon would most likely extend to other poorly
soluble particles with low cytotoxicity, regardless of their
size.
Methods
Animals
Specific pathogen-free male Fischer 344 rats (Harlan;
Frederick, MD; 175–200 g body weight) were housed in
filter-top plastic cages and given free access to food
(5001; Purina Mills, LLC, St. Louis, MO) and water in a
humidity and temperature controlled room with a 12 hr
light–dark cycle. Prior to use in experimental protocols,
all animals were acclimated for at least 1 week in an
Association for Assessment and Accreditation of Labora-
tory Animal Care International-accredited facility. Animals
were treated humanely and with regard to the alleviation
of suffering in accordance with a protocol that was ap-
proved by the University of Rochester’sC o m m i t t e eo n
Animal Resources. Animals were randomly distributed
among the treatment groups, with 3–5r a t sp e rg r o u pf o r
dosimetry and separate groups of 5 rats for assessing acute
inflammatory parameters.
Achieving similar deposited doses of TiO2
A high deposited dose of ~200 μg TiO2 was selected so
that we could compare our findings with existing data
sets generated in our own laboratory and other literature
reports [34,52,72,73]. The lower dose of ~45 μgw a s
chosen after performing preliminary experiments that
interrogated the dose response curve for neutrophil influx
24 hr after intratracheal instillation, in which we began
observing significant inflammatory effects compared to
saline controls. While it is straightforward to achieve
the target doses for instillation exposures, lower RT
deposition fractions derived from the Multiple Particle
Path Dosimetry (MPPD) model [74] were used to calcu-
late aerosol concentrations that would produce the desired
doses upon inhalation exposure. In addition, the deposited
doses (ILBs) following inhalation and intratracheal instilla-
tion exposures were verified through quantification of Ti
content in lung tissue (see below).
Whole body inhalation exposures
Whole body inhalation was used as a low dose rate de-
livery method. Other exposure methods, such as nose-
only inhalation, can minimize the deposition of NPs on
the animals’ skin and fur and thus reduce oral uptake of
NPs. However, a significant disadvantage to such methods
is that the animals are subjected to higher levels of stress
and would not be acclimated to exposure conditions fol-
lowing a single or even repeated exposure for only 4 days
[75]. Due to the uncertain contribution of this stress to
response outcomes, we decided to compare our intratra-
cheal instillation response outcomes to those following
whole body inhalation NP exposure. Furthermore, much
of the historical literature to which we wished to compare
our results describes effects of TiO2 NPs that were deliv-
ered via whole body inhalation exposures.
Rats were randomly placed in a 60 L compartmental-
ized, polycarbonate (Lexan) chamber, which was under
slight negative pressure with an internal horizontal flow
of 35 L/min. TiO2 powder (AEROXIDE P25 powder,
Evonik, Germany; primary particle size, 25 nm; 80% ana-
tase, 20% rutile crystal phase; BET surface area 57 m
2/g,
[4]) was fed by a screw mechanism into a jet mill (JET-O-
MIZER™, Fluid Energy Equipment Division, Telford, PA),
Figure 5 HO-1 levels in lung homogenates and BALF cell
pellets following single high dose exposure to TiO2 NPs. HO-1
levels in lung homogenates (A) and BALF cell pellets (B) following
inhalation (blue squares) or instillation (green circles) exposure. Values
are group means±SE (n=5) and represented as percentage of con-
trols. *, significantly different from corresponding controls; Φ, signifi-
cantly different between exposure methods (p<0.05).
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3
or 13 ± 1 mg/m
3 (for 4 hr). The higher aerosol concentra-
tion of 33 ± 4 mg/m
3 was used to achieve the higher de-
posited dose for the single exposure. The 13 ± 1 mg/m
3
aerosol concentration was used for the single, low
deposited dose and also for the repeated exposure for 4 hr
over 4 consecutive days. Control animals were exposed to
filtered air. The TiO2 aerosol mass concentrations were
determined gravimetrically via filter (PALLFLEX® Emfab;
PALL Life Sciences, Port Washington, NY) samples drawn
Figure 6 BALF cellular and biochemical parameters following repeated high dose exposure to TiO2 NPs. The numbers of cells (A),
macrophages (B), and neutrophils (C), and LDH (D) and β-glucuronidase activities (E) were assessed 24 hr post inhalation (blue squares)o r
instillation (green circles) exposure. Values are group means±SE (n=5). *, significantly different from corresponding controls; Φ, significantly different
between exposure methods (p<0.05).
Table 5 BALF cellular and biochemical parameters following repeated exposures to TiO2 NPs at different dose rates
Whole body inhalation Intratracheal instillation
Air TiO2 Saline TiO2
Cell viability (%) 95.1 ± 1.4 95.1 ± 2.5 95.0 ± 2.3 94.2 ± 0.8
Total cells (Number ×10
7) 1.33 ± 0.10 1.17 ± 0.23 1.68 ± 0.06Φ 2.20 ± 0.22*Φ
Alveolar macrophages (%) 98.7 ± 0.4 97.7 ± 0.5 97.9 ± 0.6 81.2 ± 3.8*Φ
(Number ×10
7) 1.31 ± 0.10 1.14 ± 0.22 1.64 ± 0.06Φ 1.79 ± 0.23
Neutrophils (%) 0.8 ± 0.2 1.6 ± 0.6* 1.2 ± 0.3 16.8 ± 3.6*Φ
(Number ×10
5) 1.02 ± 0.36 1.96 ± 1.00 2.00 ± 0.60Φ 36.59 ± 6.60*Φ
Lymphocytes (%) 0.6 ± 0.2 0.7 ± 0.2 0.8 ± 0.5 2.1 ± 0.5*Φ
(Number ×10
4) 7.62 ± 2.25 7.53 ± 2.45 14.05 ± 7.29 45.99 ± 11.86*Φ
LDH release (nmol/min/mL) 46.83 ± 3.72 61.19 ± 4.62* 41.72 ± 3.48 58.81 ± 9.43*
β-Glucuronidase activity (nmol/min/mL) 0.25 ± 0.06 0.25 ± 0.09 0.33 ± 0.09 0.40 ± 0.20
BALF protein (mg/mL)
a 0.12 ± 0.01 0.15 ± 0.02 0.12 ± 0.01 0.13 ± 0.01
Values are group means (n = 5)± SD for inhalation (4 hr duration) and instillation exposures at 24 hr post beginning of exposure. *, significantly different from
corresponding controls; Φ, significantly different from whole body inhalation at the same post-exposure time point;
a, significant main effect of TiO2
exposure (p < 0.05).
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MMAD was determined by an eight-stage Nano-MOUDI
impactor (MSP Corp., Shoreview, MN) and the CMD by a
model 1000XP wide range particle spectrometer (MSP
Corp.). The size characteristics of the TiO2 aerosols were
similar for the single and repeated exposure concentra-
tions (Table 1).
Intratracheal instillation exposures
TiO2 NPs were cup horn sonicated (Sonics VCX 750
Vibra Cell, Sonics and Materials, Inc., Newtown, CT) for
5 sec at 29% amplitude in 0.9% sterile saline and vor-
texed for ~30 sec immediately prior to intratracheal
instillation. For the experiments in Additional file 1:
Figure S1, the NPs were sonicated for 5 sec, 5 min or
30 min in either dispersion medium or saline. Rats were
anesthetized with 4.5% isoflurane until their breathing
was slow and shallow, after which the rats were placed in
a supine position with the head elevated. A modified
pediatric otoscope was used to visualize the vocal cords. A
20 gauge, 1.5 inch, Teflon® catheter sheath was inserted
through the vocal cords until the tip was ~3-5 mm above
the bronchial carina. In synchrony with the inspiratory
phase of the breathing cycle, 250 μL of the TiO2 suspen-
sion was instilled into the lung. Controls were exposed to
saline that was sonicated as described above. Mock intra-
tracheal instillations directly into platinum crucibles
showed that no significant losses of TiO2 occurred in the
instillation needle or syringe when compared to the de-
posited doses in the lungs.
The hydrodynamic size of a 1:10 dilution of the 800
μg/mL suspension of TiO2 for intratracheal instillation
was determined by DLS (Nano ZS Zetasizer, Malvern
Instruments, Westborough, MA) and LDS (Partica LA-
950 V2; Horiba Instruments, Inc., CA) as previously de-
scribed [18]. The measurements by DLS and LDS were
taken after the material was sonicated for ~5 sec and then
vortexed for ~30 sec, every 15 minutes for 1 hr, mimicking
the preparation used prior to instilling the material and
accounting for the time it takes to instill all of the rats in
one group (~1 hr).
Dissolution of TiO2
The dissolution rate of TiO2 NPs was determined with a
dynamic flow-through system as previously described
[76]. Briefly, NPs (~0.8 mg) were suspended in 1 mL of
dissolution buffer before being injected into the upper
chamber of a dialysis cell fitted with a 3,500 molecular
weight cellulose ester asymmetric membrane (Spectra/
Pore®, Gardena, CA; effective pore size ~3.5 nm). The
Ti-free dissolution buffers simulated extracellular lung
lining fluid (pH =7.4) and intraphagolysosomal fluid
(pH =4.5), respectively. The buffers flowed into the dia-
lysis cells at a rate of 60 μL/min, or ~3 mL/hr; the outlet
ports of the dialysis cells were connected to a fraction
collector. The dialysis cells were submerged in a 37°C
water bath in a dark room. A fraction collector with
metal-free, pre-weighed polypropylene tubes was used to
collect the dialysates over the course of 7 days. The sam-
ple weight for each tube was recorded. The solubilized
amount of Ti in the fractions were all below the instru-
ment limit of detection (~10 ng/mL) by atomic emission
spectroscopy (Beckman Spectraspan V, Fullerton, CA).
Quantification of TiO2 NPs in lung tissues
TiO2 NP-exposed rats were euthanized with an overdose
of 2, 2, 2-tribromoethanol (Avertin; 25 mg/100 g body
weight, i.p.); the pelts were removed to eliminate possible
transfer of TiO2 to the lung tissue from the animals’ fur
as previously described [77]. Lung tissues were harvested
immediately following exposure (ILB), 24 hr and 7 days
post exposure by excising the lung above the bifurcation of
the main bronchi. Tissue samples were dried at 85°C and
then ashed at low temperature (50–100°C) in a solid state
plasma asher (March Instruments Inc., Concord, CA), in
which organic material is gently oxidized to CO2,l e a v i n g
only TiO2 and inorganic ash. Samples were then fused
with sodium carbonate/sodium borate (2:1; Sigma, St.
Louis, MO) at 1500°C in platinum crucibles for 20 min or
until a clear melt was formed. The melt was cooled and
then dissolved in 2.5 N sulfuric acid and diluted 1:2 with
ultra pure water. The concentration of Ti was quantified
using atomic emission spectroscopy and the mass of TiO2
in each sample was then determined stoichiometrically.
Control and naïve animals were found to have background
levels of TiO2 in the lung below the instrument limit of
detection for atomic emission spectroscopy (~10 ng/mL).
Figure 7 Percentage of neutrophils 24 hr after single and
repeated exposure to high dose TiO2 at different dose rates.
The percentage of neutrophils in BALF at 24 hr post inhalation
(blue squares) or instillation (green circles) exposure plotted according
to deposited dose rate (~0.21, repeated inhalation; ~0.71, high dose
single inhalation; ~5,400, repeated instillation; and ~240,000 μg/min,
high dose single instillation). Symbols are group means± SE (n=5).
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lavage fluid
Separate groups of rats were euthanized at 4, 8, 24 hr
and 7 days after instillation or after the beginning of the
inhalation exposures with an overdose of Avertin followed
by exsanguination. The lung/heart block was excised and
excess tissue removed prior to the lungs being lavaged
with sterile, 0.9% saline (5 × 5 mL), keeping the first
two lavage supernatants separate from the remaining
ones following centrifugation (10 min, 350 × g, 4°C). BAL
cell viability (trypan blue exclusion), number, and the per-
centage of different cell types (Hema 3®; Fisher Scientific,
Kalamazoo, MI) were determined. Total protein concen-
tration was measured as an indicator of cytotoxicity and
epithelial barrier permeability with the bicinchoninic
acid (BCA) assay using reagents purchased from Thermo
Scientific (Rockford, IL). Lactate dehydrogenase and β-
glucuronidase activities, as indicators of cell membrane
and lysosomal membrane integrity, respectively, were de-
termined using reagents from Sigma.
Preparation of lung homogenates
Flash frozen, right lung tissues were homogenized on ice
for 30 sec in 4.5 mL of radioimmunoprecipitation assay
(RIPA) buffer, comprised of reagents from Sigma (50 mM
Tris–HCl, 150 mM NaCl , 0.25% deoxycholic acid, 1 mM
EDTA, 0.1 mM PMSF) and Roche (Indianapolis, IN; 1%
nonindet P-40, 10 μg/mL aprotinin and 10 μg/mL leupep-
tin). Samples were centrifuged for 1 hr at 19,800 × g and
4°C in 50 mL, round PPCO tubes (Nalgene, Rochester,
NY). The protein content of the supernatants was mea-
sured using the BCA assay.
Measurements of inflammatory mediators
T h el u n gh o m o g e n a t ea n dt h eB A Lf l u i ds u p e r n a t a n t sw e r e
used for measuring MCP-1, MIP-2 (CXCL2/CINC-3),
TNF-α, and IL-10 levels by ELISA using antibodies and
protocols from BD Biosciences (San Diego, CA), R&D
Systems (Minneapolis, MN), eBioscience (San Diego, CA)
and Invitrogen (Frederick, MD), respectively. HO-1 in
BALF cell pellet lysates (lysis buffer: 1.25x protease inhibi-
tor cocktail P2714 from Sigma, 1% Triton X and 0.2 mM
PMSF) and supernatants were also assessed by ELISA
(Enzo Life Sciences, Farmingdale, NY).
Data analysis
The dosimetry results were analyzed for time related
changes from ILB by one-way ANOVAs for both expos-
ure methods. Differences between the exposure methods
at the same post-exposure time points were assessed by
aS t u d e n t ’s t-test. Response endpoints for the high dose
single exposures were analyzed by two-way ANOVA to de-
tect differences over time and between exposure methods.
Separate control groups for every post-exposure time point
were not included due to ethical reasons, specifically to
limit the total number of animals used in the study, as it
was not considered likely that within-exposure-method re-
sponses in controls would change consistently over the
time course of this study. Therefore, controls were evalu-
ated only at 24 hr post exposure (the endpoint of highest
possible acute inflammation) and 4 hr post (the earliest
t i m ep o i n ta s s e s s e df o rt h eo n s e to ft h ei n f l a m m a t o r yr e -
sponses). Responses in controls were only found to have
significant time related differences within inhalation expos-
ure for cell viability, BALF MCP-1 and homogenate MIP-2
and within instillation exposure for BALF protein, hom-
ogenate MIP-2, IL-10 and BALF pellet HO-1. Because
there was no consistency in terms of which time point had
higher values and the small differences were not likely to
be biologically significant, the controls were pooled. The
low dose response and repeated exposure data were ana-
lyzed by two-way ANOVAs with exposure method and
dose of TiO2 as the main factors. Data were appropriately
transformed if analyses of residuals suggested deviations
from the assumptions of normality and equal variance.
Two outliers were identified based on analyses of residuals
(β-glucuronidase and BALF protein) and were removed
from figures, tables and corresponding ANOVA tests. All
comparisons were considered statistically significant when
p< 0.05.
Additional file
Additional file 1: Figure S1. Suspension and Sonication Time Effects
on the Inflammatory Response. The neutrophil response 24 hr post
intratracheal instillation with TiO2 that was: (A) suspended in DM (red) or
saline (green) and cup horn sonicated for 5 sec;
(B) suspended in saline and cup horn sonicated for 5 sec (solid green),
5 min (green dots), or 30 min (green checkers). Bars are group means
(n=5) ±SE and are shown as a percentage of corresponding controls
(DM or saline). In A the *indicate a significant increase from
corresponding control and Φ indicates a significant difference between
dispersants as determined by a two-way ANOVA (p <0.05).
In B the *indicate significant increases from corresponding control and
Ω indicate significant differences from the other two sonication times as
determined by a two-way ANOVA (p< 0.05).
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